InflaRx N.V. (IFRX)
InflaRx develops drugs that block the inflammatory protein C5a, with vilobelimab sold to hospitals for COVID-19 patients. It last closed at $1.15 on Nov 17, down 2.54% on the day. In the past 30 days there were 1 dark pool print totaling $408K, the largest $408K.
Key Stats
Last 12 monthsNot reported for this period.
From IFRX's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 20). Last 12 months adds up the four latest quarters. Figures are in EUR. Per share figures are left out because the US listing can represent a different number of shares.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 1 analyst who set a price target on IFRX in the past 90 days. The average target is $8.00, with a high of $8.00 and a low of $8.00, compared with the last close of $1.15.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 14 | Needham | Initiated | Buy | $8 |
| Aug 7 | Cantor Fitzgerald | Maintained | Buy | $6 |
| May 13 | Raymond James | Upgrade | Buy | $9 |
Technical Analysis
The stock is 26% below its 20 day and 44% below its 50 day average. It is 44% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 31), near oversold. The nearest support is the Pivot at $1.14, and the nearest resistance the Pivot R1 at $1.20.
| RSI (14) | 30.79 | Weak, oversold below 30 | Neutral |
| MACD | -0.14 | Below its signal line | Bearish |
| Stochastic | 5.7 | Near the bottom of its range | Oversold |
| ADX (14) | 31.1 | Trending down | |
| Williams %R | -90.8 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -108.6 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −29.0% | Change over 10 sessions | Bearish |
| ATR (14) | $0.13 | Typical daily range, 11.2% of price |
| RSI (14) | 37.82 | Weak, oversold below 30 | Neutral |
| MACD | -0.12 | Below its signal line | Bearish |
| Stochastic | 5.4 | Near the bottom of its range | Oversold |
| ADX (14) | 23.2 | Weak trend | |
| Williams %R | -95.4 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -162.2 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −45.0% | Change over 10 sessions | Bearish |
| ATR (14) | $0.32 | Typical daily range, 27.6% of price |
What happened before
See how IFRX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How IFRX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.
Whale Options Flow
90DNo whale options trades in IFRX in the last 90 days.
Dark Pool
30DIFRX Institutional Ownership
Full report →- ▲35 buying vs 22 selling
- ▲Shares held by funds +3.5%
- ▲Funds holding +2
- ▲Superinvestors: 3 added, 0 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 64 | 62 | +3.2% |
| In funds' top 10 | 0 | 0 | – |
| Held by funds | – | – | – |
| New / increased | 12 / 23 | 30 / 13 | −18.6% |
| Reduced / sold out | 13 / 9 | 7 / 3 | +120.0% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IFRX is in one of them and how their past IFRX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered IFRX in an article yet. Here's the latest on the wider market.
About InflaRx N.V.
InflaRx is a biopharmaceutical company based in Jena, Germany, that develops treatments aimed at blocking C5a, a protein that drives inflammation. Its approved product, vilobelimab, is given intravenously and is sold in the U.S. under the name GOHIBIC, where hospitals can order it for critically ill COVID-19 patients. Its lead candidate, izicopan, is taken by mouth and is being studied for chronic skin conditions such as hidradenitis suppurativa and chronic spontaneous urticaria.
- Headquarters
- Jena, Germany


